Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir + Peginterferon alfa-2a + Ribavirin in HCV/HIV-1 Coinfected Subjects (Phase 3, Germany)
2011-002668-25Phase 3Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of telaprevir in hepatitis C virus infection and Human immunodeficiency virus infection type 1, sponsored by Vertex Pharmaceuticals. Primary endpoint: SVR12. Started Nov 2011; status: terminated.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infectionHuman immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2011-002668-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002668-25.